ID   Caco-2 Cu Pro-R
AC   CVCL_YP11
SY   Cu Pro-R Caco-2; Cu Pro-R
DR   cancercelllines; CVCL_YP11
DR   Wikidata; Q93441262
RX   PubMed=31981602;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:29036; Copper(2+).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0025 ! Caco-2
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 05-10-23; Version: 8
//
RX   PubMed=31981602; DOI=10.1016/j.tiv.2020.104773;
RA   O'Doherty C., Keenan J., Henry M., Meleady P., Sinkunaite I.,
RA   Clynes M., O'Sullivan F., Horgan K., Murphy R.;
RT   "Characterisation and proteomic profiling of continuously exposed
RT   Cu-resistant variants of the Caco-2 cell line.";
RL   Toxicol. In Vitro 65:104773.1-104773.14(2020).
//